Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 14
    records per page




    CT as a Tool to Depict Pulmonary Fibrosis MESHD Pulmonary Fibrosis HP in Patients With COVID-19: a Radiopathological Correlation 

    Authors: Anna Alguersuari; Miguel Angel Carrasco; Gemma Munné; Maria Eulalia Oliva; Cristina Simon; Maria Dolores Bosque; Melcior Martínez; Natalia Lugo; Xavier Herranz; Mariana Rovira

    doi:10.21203/rs.3.rs-44197/v1 Date: 2020-07-16 Source: ResearchSquare

    OBJECTIVESCT findings of COVID-19 infected patients has been well described, but it it’s roll in depicting signs of fibrosis MESHD in critically ill patients remains unclear. To our knowledge, there are no radiopathological correlations of the pulmonary pathology. Exudative and proliferative diffuse alveolar damage (DAD) are the most commonly reported injury. Few studies describe fibrosis MESHD, the last phase of DAD. Our study correlates post-mortem chest US and CT findings of COVID-19 infected patients with the histopathology from biopsies taken of the lung. It focuses on the role of CT to depict fibrosis MESHD. METHODSThis is a prospective observational study of six consecutive deceased patients infected with COVID-19. Post-mortem chest CTs and US were performed within 24 hours of death MESHD. CT and US were used to obtain biopsies of different radiological patterns. Pre-mortem CT examinations were also retrospectively evaluated. RESULTSOn CT, all patients presented with extensive areas of consolidation and ground-glass opacities affecting most segments of the lung. Pleural effusion MESHD Pleural effusion HP was present in all cases. Four of the patients showed signs of fibrosis MESHD. On US, subpleural consolidation, pleural thickening HP, and B-pattern were present.All patients showed different stages of DAD, mostly proliferative DAD. Four patients presented with fibrotic DAD, all of which had been admitted for over three weeks and correlated with the CT findings of fibrosis MESHD. CONCLUSIONIn our study, signs of fibrosis MESHD on CT show a histopathological correlation. CT may be useful to identify the group of COVID-infected patients that develop fibrosis MESHD as a marker of poor prognosis, in the late stage of the disease MESHD.

    In silico immune infiltration profiling reveals the role of naïve B cells in lung tissues of COVID-19 patients

    Authors: Yi-Lin Chiu; Yi-Ying Wu; Sheng-Huei Wang; Chih-Hsien Wu; Li-Chen Yen; Hsing-Fan Lai; Chin-Liang Ho

    doi:10.21203/rs.3.rs-37877/v1 Date: 2020-06-25 Source: ResearchSquare

    COVID-19 caused by SARS-CoV-2 has rapidly spread to more than 160 countries worldwide since 2020. Despite the tremendous efforts and resources spent around the world trying to explore antiviral drugs, there is still no effective clinical treatment for COVID-19. Approximately 15% of COVID-19 cases progress to pneumonia MESHD pneumonia HP, patients with severe pneumonia MESHD pneumonia HP may die from acute respiratory distress HP syndrome MESHD (ARDS). In addition, further pulmonary fibrosis MESHD pulmonary fibrosis HP from SARS-CoV-2 infection MESHD causes ARDS that often leads to irreversible impairment of lung function. If the mechanisms by which SARS-CoV-2 infection MESHD primarily cause immune responses or immune cell infiltration can be identified, it is possible to alleviate or prevent severe lung damage by modulating the infiltration and activation of specific immune cells to mitigate excessive immunity response.The extent to which subsets of immune cells are significantly altered in the lung tissue of COVID-19 patients remains unclear. This study applied the CIBERSORT method to comprehensively evaluate the immune infiltration landscape in lung tissues of COVID-19 patients, and further compared with the one from lung tissue of patients with idiopathic pulmonary fibrosis MESHD pulmonary fibrosis HP (IPF). We found several immune cell subtypes; particularly naïve B cells are highly infiltrated in COVID-19 group. A comparison of functional gene set analysis revealed that non-differentiated naïve B cells may be the main cause of the overactive humoral immune response. We further compared several specific COVID-19 cases receiving therapies targeting B cells and found that appropriate suppression of naïve B cells might be a new strategy to alleviate severe symptoms of COVID-19.

    The Efficacy of Treating Pulmonary Fibrosis MESHD Pulmonary Fibrosis HP and Pulmonary Function Injury in COVID-19 with the Fuzheng Huayu Tablets: study protocol for a multicenter randomized controlled trial

    Authors: Fei Jing; Haina Fan; Zhimin Zhao; Feng Xing; Yingchun He; Chenghai Liu

    doi:10.21203/rs.3.rs-37422/v1 Date: 2020-06-22 Source: ResearchSquare

    Background: Some patients with COVID-19 have been found pulmonary dysfunction and/or fibrosis MESHD in the recovery period, especially severe cases, but there are no certain drugs or treatment to cope with this situation. Previous studies proved the efficacy of FZHY on lung fibrosis MESHD induced by Bleomycin in animals and improvement of pulmonary function in COPD patients. We design this trial to carry out the clinical study that the effects of FZHY Tablets on pulmonary fibrosis MESHD pulmonary fibrosis HP and/or pulmonary function injury in the recovery period of COVID-19 and expect to improve the prognosis.Methods/design: This is a double-blind, placebo-controlled, randomized, multicenter clinical trial. It enrolls 160 patients who had been diagnosed with COVID-19, but currently they are negative for viral testing and have developed pulmonary fibrosis MESHD pulmonary fibrosis HP or pulmonary dysfunction. They are randomly divided equally into control group and experimental group. All patients are given basic treatment such as respiratory function rehabilitation training and vitamin C. The control group is given placebo of FZHY, and the experimental group is given FZHY. Each patient will be observed for 24 weeks and followed up for 8 weeks. The primary outcome for the trial is a composite endpoint consisting of lung function and HRCT. Secondary outcomes include clinical symptoms, oxygen saturation and quality of life assessment. Discussion: The trial is designed to test the hypothesis that treating pulmonary fibrosis MESHD pulmonary fibrosis HP or pulmonary dysfunction after SARS-CoV-2 infection MESHD with FZHY will improve the patient’s lung function or the pathological manifestation of pulmonary fibrosis MESHD pulmonary fibrosis HP, and improve the quality of life. Trial registration: Clinical Trials.gov, ID: NCT04279197. Registered on 12 April 2020.

    CT features of COVID-19 patients with two consecutive negative RT-PCR tests after treatment

    Authors: Zhao Fu; Ningning Tang; Yanqing Chen; Longbai Ma; Youyong Wei; Yumin Lu; Kun Ye; Hang Liu; Fen Tang; Guangyi Huang; Yingxia Yang; Fan Xu

    doi:10.21203/rs.3.rs-33163/v1 Date: 2020-06-02 Source: ResearchSquare

    Purpose: The objective of this study is to expound the CT features of COVID-19 patients whose nucleic acid tests converted to negative after treatment.Materials and Methods: We retrospectively reviewed 46 COVID-19 patients with two consecutive negative RT-PCR tests after treatment. The cases were divided into moderate group and severe/critical group according to disease MESHD severity. Clinical and CT scanning data were collected. CT signs of pulmonary lesions and the score of long involvement were expounded.Results: 39 moderate cases and 7 severe/critical cases were included. All moderate patients showed peripheral lesions while severe/critical cases exhibited both central and peripheral lesions with all lobes involvement. Ground glass opacity (GGO) and mixed GGO were observed. Aberrant pulmonary interstitium manifested as reticular and thin linear pattern. Thickened blood SERO vessels and pleural thickening HP were found. Pulmonary fibrosis MESHD Pulmonary fibrosis HP, annular thickening of the bronchial wall, bronchiectasis MESHD bronchiectasis HP, air bronchogram and small amount of bilateral pleural effusion MESHD pleural effusion HP were observed in severe/critical patients. The severe/critical group showed higher CT score of involvement.Conclusions: Pulmonary lesions persisted even after twice consecutive nucleic acid tests converted to negative. We strongly recommended regular follow-up of CT scans after nucleic acid tests conversion. Evaluation of complete remission should base on chest CT.

    Vitamin D deficiency MESHD in critically ill patients diagnosed with COVID -19. Are we doing enough? A retrospective analysis of 226 patients.

    Authors: Tomás Cuñat; Antonio Ojeda; Andrea Calvo

    doi:10.21203/rs.3.rs-30390/v1 Date: 2020-05-19 Source: ResearchSquare

    Vitamin D deficiency MESHD is common in critically ill patients, and its role in COVID-19 patients could be important. Its deficiency has been associated with respiratory distress HP syndrome MESHD, pulmonary fibrosis MESHD pulmonary fibrosis HP (through activation of the renin-angiotensin system), increased levels of IL-2, and cardiovascular adverse events. Various scientific societies recommend the screening of vitamin D in individuals at risk for deficiency. Despite that, the demographics of Vitamin D levels amongst critically ill patients with a confirmed diagnosis of COVID-19 are currently unknown. We propose a study to determine the prevalence SERO of vitamin D deficiency MESHD in a consecutive population of COVID-19 patients admitted to intensive care units and to evaluate its relationship with clinical outcomes. We study 226 COVID-19 patients between March 16 and April 26, 2020. The prevalence SERO of vitamin D deficiency MESHD could not be determined because the value of 25-hydroxyvitamin D was obtained in a few patients (17 patients, 7,5%). However, all patients with serum SERO determinations of 25-hydroxyvitamin D presented a level lower than 20 ng/ml and thirteen patients (76,5%) levels < 12,5 ng/ml. We conclude that undiagnosed vitamin D deficiency MESHD is common in critically ill COVID-19 patients, and physicians should be conscious of the relevance of its monitoring and supplementation.

    THE MUC5B PROMOTOR POLYMORPHISM ASSOCIATES WITH SEVERE COVID-19

    Authors: Coline H.M. van Moorsel; Joanne J van der Vis; Claudia Benschop; Henk J.T. Ruven; Marian Quanjel; Jan C Grutters

    doi:10.1101/2020.05.12.20099333 Date: 2020-05-16 Source: medRxiv

    Background Diversity in response to exposition to severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) is common and may be related to the innate immune response. The mucin MUC5B is an important component of the innate immune response and expression levels are associated with the MUC5B promoter polymorphism, rs35705950. The high expressing T-allele of rs35705950 is an accepted risk allele for a non-infectious aging lung disease MESHD called idiopathic pulmonary fibrosis MESHD pulmonary fibrosis HP (IPF). However, given the theory of trade-offs in aging lung disease MESHD and the importance of high expression for an adequate immune response, we hypothesize that the T-allele is protective against severe coronavirus disease MESHD 2019 (COVID-19). Methods We collected demographics, radiology, survival data and MUC5B rs35705950 allele status for 108 patients requiring hospitalisation for COVID-19 at St Antonius Hospital in The Netherlands. For comparison of allele frequencies and allele carriership with a white control cohort, the patient cohort was divided in a white (n=83) and non-white cohort. Results The patients had a median age TRANS of 66 years and consisted predominantly of males TRANS (74%) and 23 patients (21%) died. The T-allele frequencies of rs35705950 in white patients was 0.04 which was significantly lower than the T-allele frequency of 0.10 in white controls (p= 0.02). Moreover, comparison of the number of carriers TRANS and non- carriers TRANS of the T allele showed that only 8.4% of patients carried the T-allele versus 18% of controls (p=0.029; OR= 0.41, CI=0.19-0.94). Conclusions The MUC5B rs35705950 promoter polymorphism associates with COVID-19. The risk allele (T) for IPF is protective against the development of severe COVID-19 disease MESHD. This is a further example of a trade-off between optimal expression levels in the respiratory system which associates with aging diseases MESHD. However, these results require further investigation.

    Identification of pulmonary comorbid diseases MESHD network based repurposing effective drugs for COVID-19

    Authors: Jai Chand Patel; Rajkumar Tulswani; Pankaj Khurana; Yogendra Kumar Sharma; Lilly Ganju; Bhuvnesh Kumar; Ragumani Sugadev

    doi:10.21203/rs.3.rs-28148/v1 Date: 2020-05-08 Source: ResearchSquare

    The number of hospitalization of COVID-19 patients with one or more comorbid diseases MESHD is highly alarming. Despite the lack of large clinical data and incomplete understanding of virus pathology, identification of the COVID-19 associated diseases MESHD with clinical precision are highly limited. In this regard, our text mining of 6238 PubMed abstracts (as on 23 April 2020) successfully identified broad spectrum of COVID-19 comorbid diseases MESHD/disorders (54), and their prevalence SERO on the basis of the number of occurrence of disease MESHD terms in the abstracts. The disease MESHD ontology based semantic similarity network analysis revealed the six highly comorbid diseases MESHD of COVID-19 namely Viral Pneumonia MESHD Pneumonia HP, Pulmonary Fibrosis MESHD Pulmonary Fibrosis HP, Pulmonary Edema MESHD Pulmonary Edema HP, Acute Respiratory Distress HP Syndrome MESHD (ARDS), Chronic Obstructive Pulmonary Disease MESHD Chronic Obstructive Pulmonary Disease HP (COPD) and Asthma MESHD Asthma HP. The disease MESHD gene bipartite network revealed 15 genes that were strongly associated with several viral pathways including the corona viruses may involve in the manifestation (mild to critical) of COVID-19. Our tripartite network- based repurposing of the approved drugs in the world market revealed six promising drugs namely resveratrol, dexamethasone, acetyl cysteine, Tretinoin, simvastatin and aspirin to treat comorbid symptoms of COVID-19 patients. Our animal studies in rats and literatures strongly supported that resveratrol is the most promising drug to possibly reduce several comorbid symptoms associated with COVID-19 including the severe hypoxemia HP induced vascular leakage. Overall, the anti-viral properties of resveratrol against corona virus could be readily exploited to effectively control the viral load at early stage of COVID-19 infection MESHD through nasal administration.

    Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study

    Authors: Puyu Shi; Guoxia Ren; Jun Yang; Zhiqiang Li; Shujiao Deng; Miao Li; Shasha Wang; Xiaofeng Xu; Fuping Chen; Yuanjun Li; Chunyan Li; Xiaohua Yang; Zhaofeng Xie; Zhengxia Wu; Chen Mingwei

    doi:10.21203/rs.3.rs-26416/v1 Date: 2020-05-01 Source: ResearchSquare

    Background: The mortality of COVID-19 differs between countries and regions. By now, reports on COVID-19 are largely focused on first-generation cases. This study aimed to clarify the clinical characteristics of imported and second-generation cases. Methods : This retrospective, multicenter cohort study included 134 confirmed COVID-19 cases from 9 cities outside Wuhan. Epidemiological, clinical and outcome data were extracted from medical records and were compared between severe and non-severe cases. We further profiled the dynamic laboratory findings of some patients.  Results : 34.3% of the 134 patients were severe cases, and 11.2% had complications. As of March 7, 2020, 91.8% patients were discharged and one patient (0.7%) died. Age TRANS, lymphocyte count, C-reactive protein, erythrocytes edimentation rate, direct bilirubin, lactate dehydrogenase, hydroxybutyrate dehydrogenase showed difference between severe and no-severe cases (all P<0.05). Baseline lymphocyte count was higher in the survived patients than in the non-survivor case, and it increased as the condition improved, but declined sharply when death MESHD occurred. The interleukin-6 level displayed a downtrend in survivors, but rose very high in the death MESHD case. Pulmonary fibrosis MESHD Pulmonary fibrosis HP was found on later chest CT images in 51.5% of the pneumonia MESHD pneumonia HP cases. Conclusion : Imported and second-generation cases outside Wuhan had a better prognosis than initial cases in Wuhan. Lymphocyte count and IL-6 level could be used for evaluating prognosis. Pulmonary fibrosis MESHD Pulmonary fibrosis HP as the sequelae of COVID-19 should be taken into account.

    Menstrual blood SERO-derived mesenchymal stem cells provide new insights into the treatment of coronavirus disease MESHD 2019 (COVID-19)

    Authors: Xin Chen; Liang Yu; Lijun Chen; Xiaoqin Zheng; Lingling Tang; Kaijin Xu; Hongliu Cai; Yu Chen; Shufa Zheng; Juan Lu; Zhenyu Xu; Qiang Zhang; Hainv Gao; Yifei Li; Jingjing Qu; Yingan Jiang; Xiaowei Xu; Charlie Xiang; Lanjuan Li

    doi:10.21203/rs.3.rs-25947/v1 Date: 2020-04-29 Source: ResearchSquare

    Background: The coronavirus disease MESHD 2019 (COVID-19) causing a cluster of respiratory infections MESHD in Wuhan, China, is identified in December 2019. The main symptoms are defined as fever MESHD fever HP, cough MESHD cough HP, shortness of breath, with early symptom of sputum, acute respiratory distress HP syndrome MESHD (ARDS), and the final lung injury MESHD and pulmonary fibrosis MESHD pulmonary fibrosis HP. Currently, there is no effective method to cure it. Mesenchymal stem cell (MSC) therapy is an immediate need for treating COVID-19 especially severe patients at present.Methods: We describe the two confirmed case TRANS of COVID-19 severe patients in Hangzhou, China to explore the role of menstrual blood SERO-derived MSC in the treatment of SARS-CoV-2 infection MESHD. Furthermore, we mimic disease MESHD model of pulmonary fibrosis MESHD pulmonary fibrosis HP in mice to assess the role of MSC. Then, a co-culture system to investigate the underlying mechanism between MSC and pulmonary-associated cells by a series of Physiological, biochemical, bioinformatics analysis.Results: MSC transplantation increases the immune indicators (including lymphocytes) and decreases inflammatory indicators (such as IL-6, IL-10, TNF, and IFN). More importantly, the two patients alleviated symptom and discharged after 3 weeks’ treatment with MSC. Additionally, MSCs exhibit an anti-inflammatory role through suppressing some inflammatory factors (RANTES, GM-CSF, MIG-1g, MCP-5, Eotaxin), which is anastomotic to current clinical study using MSC to treat COVID-19. Conclusions: This is the first report using menstrual blood SERO-derived MSC in treating COVID-19 patients. From our clinical results, we hold one idea that MSCs reduced inflammatory effect to defend cytokine storm. The underlying mechanism is probably that MSCs inhibit epithelia cell apoptosis and reduce the secretion of inflammatory factors to prevent myofibroblasts activity. MSC provides an alternative method for treating COVID-19 particularly some patients with ARDS or subsequent pulmonary fibrosis MESHD pulmonary fibrosis HP.Trial registration: This clinical trial was submitted to and approved by the Ethics Committee of the First Affiliated Hospital, Collage of Medicine, Zhejiang University. MSC administration in patient with COVID-19 was conducted in a single center and open-label clinical trial (ChiCTR2000029606).

    Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study

    Authors: Puyu Shi; Guoxia Ren; Jun Yang; Zhiqiang Li; Shujiao Deng; Miao Li; Shasha Wang; Xiaofeng Xu; Fuping Chen; Yuanjun Li; Chunyan Li; Xiaohua Yang; Zhaofeng Xie; Zhengxia Wu; Mingwei Chen

    doi:10.1101/2020.04.19.20071472 Date: 2020-04-23 Source: medRxiv

    Background The mortality of COVID-19 differs between countries and regions. By now, reports on COVID-19 are largely focused on first-generation cases. This study aimed to clarify the clinical characteristics of imported and second-generation cases. Methods This retrospective, multicenter cohort study included 134 confirmed COVID-19 cases from 9 cities outside Wuhan. Epidemiological, clinical and outcome data were extracted from medical records and were compared between severe and non-severe cases. We further profiled the dynamic laboratory findings of some patients. Results 34.3% of the 134 patients were severe cases, and 11.2% had complications. As of March 7, 2020, 91.8% patients were discharged and one patient (0.7%) died. The median age TRANS was 46 years. The median interval from symptom onset TRANS to hospital admission was 4.5 (IQR 3-7) days. The median lymphocyte count was 1.1*109/L. Age TRANS, lymphocyte count, CRP, ESR, DBIL, LDH, HBDH showed difference between severe and no-severe cases (all P<0.05). Baseline lymphocyte count was higher in the survived patients than in the non-survivor case, and it increased as the condition improved, but declined sharply when death MESHD occurred. The IL-6 level displayed a downtrend in survivors, but rose very high in the death MESHD case. Pulmonary fibrosis MESHD Pulmonary fibrosis HP was found on later chest CT images in 51.5% of the pneumonia MESHD pneumonia HP cases. Conclusion Imported and second-generation cases outside Wuhan had a better prognosis than initial cases in Wuhan. Lymphocyte count and IL-6 level could be used for evaluating prognosis. Pulmonary fibrosis MESHD Pulmonary fibrosis HP as the sequelae of COVID-19 should be taken into account.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.